SurModics, Inc.

The Surmodics Sundance™ Sirolimus-Coated Balloon Catheter Earns FDA Breakthrough Device Status
Health, Medical, & Dental Supplies and Equipment

The Surmodics Sundance™ Sirolimus-Coated Balloon Catheter Earns FDA Breakthrough Device Status

Sundance™ Sirolimus-Coated Balloon will receive prioritization throughout the FDA submission and review process to provide patients and physicians timely access to medical devices EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that the United States Food...

Read More »
Packaging Products & Equipment

Surmodics Sublime™ Guide Sheath Receives FDA 510(k) Approval

Guide sheath is the first of Surmodics’ family of products designed for peripheral procedures accessed from the radial artery EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its...

Read More »
Display & Presentation Equipment

12-Month Data from Surmodics SurVeil® Drug-Coated Balloon Early Feasibility Study Presented at VIVA 2018

Study met primary endpoint and all 12-month secondary safety endpoints including 100 percent freedom from CD-TLR or TVR Results demonstrated continued clinically significant improvement in ABI, walking distance, walking speed and stair-climbing scores at 12 months EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic...

Read More »
New MatrixGuard Diluents Reduce the Risk of False Positives

New MatrixGuard Diluents Reduce the Risk of False Positives

The MatrixGuard™ Diluents consistently balances maximum blocking activity of matrix interferences by simultaneously maintaining assay signal across multiple formats. The MatrixGuard™ enables manufacturer to produce assay components to increase performance and manufacturability of immunoassays. The product improves performance of assay by lowering backgrounds and increases signal generation...

Read More »
Surmodics Announces FDA Clearance of a New .018" Low-Profile PTA Balloon Dilation Catheter
Health, Medical, & Dental Supplies and Equipment

Surmodics Announces FDA Clearance of a New .018" Low-Profile PTA Balloon Dilation Catheter

Company received FDA 510(k) clearance Continued progress in R&D whole-product solutions pipeline EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its .018” Low-Profile percutaneous...

Read More »
Surmodics Announces Global Approvals of .014" Low-Profile PTA Balloon Dilation Catheter
Health, Medical, & Dental Supplies and Equipment

Surmodics Announces Global Approvals of .014" Low-Profile PTA Balloon Dilation Catheter

The company received FDA 510(k) and CE Mark clearance EDEN PRAIRIE, Minn. - Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced it has received U.S. Food and Drug Administration (FDA) 510(k) and CE Mark clearance for its .014” low-profile percutaneous transluminal angioplasty (PTA) balloon dilation...

Read More »
Chemicals & Gases

SurModics Expands Protein-Free Stabilizer Line with AP Option

AACC Annual Meeting and Clinical Lab Expo 2014 EDEN PRAIRIE, Minn.-- SurModics IVD, Inc., a wholly owned subsidiary of SurModics, Inc. (NASDAQ:SRDX) and a market leader for in vitro diagnostic assay components, is introducing StabilZyme® Protein-Free AP Stabilizer at the American Association for Clinical Chemistry meeting currently taking place in Chicago. “Protein interference is a...

Read More »

TMB Stop Solution is non-corrosive and non-hazardous.

BioFX® Liquid Nova-Stop Solution provides non-corrosive, non-hazardous stop solution for TMB microwell substrates. While offering alternative to stop solutions that contain sulfuric acid or hydrochloric acid, product also exhibits minimal signal drift. ELISA assay kit manufacturers can include solution in their products without needing to label and ship products as corrosive, and no...

Read More »
Chemicals & Gases

SurModics IVD Breakthrough Stabilizer Addresses Industry Challenge

EDEN PRAIRIE, Minn.Â- – SurModics IVD, Inc., a wholly owned subsidiary of SurModics, Inc. (NASDAQ:SRDX) and a market leader for in vitro diagnostic assay components, is launching its new StabilZyme® Protein-Free Stabilizer today at the American Association for Clinical Chemistry (AACC) meeting in Houston. “This newest addition to SurModics’ stabilization line is significant for...

Read More »
Paints & Coatings

SurModics' New Low Friction, Low Particulate Device Coatings Introduced

SurModics Serene™ hydrophilic coatings address unmet need for lubricious, low particulate medical device coatings EDEN PRAIRIE, Minn.--SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface modification for medical devices, today introduced SurModics Serene™ lubricious coatings for endovascular medical devices. Serene coatings are a breakthrough technology that delivers lubricity and...

Read More »
People in the News

Surmodics Names Nusrath Sultana, MD, as Vice President, Clinical Affairs

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced today Nusrath Sultana, MD, has joined Surmodics as Vice President, Clinical Affairs, effective February 3, 2020. “We are fortunate to have someone of Nusrath’s caliber joining the Surmodics team,” said Gary...

Read More »
The Surmodics Sundance™ Sirolimus-Coated Balloon Catheter Earns FDA Breakthrough Device Status
Health, Medical, & Dental Supplies and Equipment

The Surmodics Sundance™ Sirolimus-Coated Balloon Catheter Earns FDA Breakthrough Device Status

Sundance™ Sirolimus-Coated Balloon will receive prioritization throughout the FDA submission and review process to provide patients and physicians timely access to medical devices EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that the United States Food...

Read More »
Company News

Surmodics Completes Enrollment in Pivotal TRANSCEND Clinical Trial

Study designed to evaluate safety, efficacy of the company’s next-generation SurVeil™ drug-coated balloon Company Raises 2019 Revenue and EPS Guidance Eden Prairie, Minn.-- (Business Wire) -- Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced it has completed enrollment in TRANSCEND, its pivotal...

Read More »
Packaging Products & Equipment

Surmodics Sublime™ Guide Sheath Receives FDA 510(k) Approval

Guide sheath is the first of Surmodics’ family of products designed for peripheral procedures accessed from the radial artery EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its...

Read More »
Company News

Surmodics Provides Update Regarding TRANSCEND Clinical Trial

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, has resumed patient enrollment into its TRANSCEND clinical trial and is nearly 75 percent of the way to its goal of 446 randomized patients. Patient enrollment in TRANSCEND, the pivotal clinical trial for the SurVeil™...

Read More »
Display & Presentation Equipment

12-Month Data from Surmodics SurVeil® Drug-Coated Balloon Early Feasibility Study Presented at VIVA 2018

Study met primary endpoint and all 12-month secondary safety endpoints including 100 percent freedom from CD-TLR or TVR Results demonstrated continued clinically significant improvement in ABI, walking distance, walking speed and stair-climbing scores at 12 months EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic...

Read More »
People in the News

Surmodics Names Teri Sides as Chief Marketing Officer

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced today Teri Sides has joined Surmodics as Senior Vice President and Chief Marketing Officer, effective November 1, 2018. "I am thrilled to welcome Teri to our internal team. Teri has been an important contributor to...

Read More »
New MatrixGuard Diluents Reduce the Risk of False Positives

New MatrixGuard Diluents Reduce the Risk of False Positives

The MatrixGuard™ Diluents consistently balances maximum blocking activity of matrix interferences by simultaneously maintaining assay signal across multiple formats. The MatrixGuard™ enables manufacturer to produce assay components to increase performance and manufacturability of immunoassays. The product improves performance of assay by lowering backgrounds and increases signal generation...

Read More »
People in the News

Surmodics Announces Leadership Change and Appointment of Interim CFO

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced today Andrew LaFrence will resign as Chief Financial Officer (CFO) effective May 25, 2018. Following LaFrence’s departure, Timothy J. Arens, Vice President of Corporate Development and Strategy, will serve as...

Read More »
Mergers & Acquisitions

Surmodics Acquires Thrombectomy Technology Assets from Embolitech, Strengthening Peripheral Vascular Whole-Product Solutions Portfolio

Surmodics’ design, development, hydrophilic coating technology and manufacturing capabilities will advance innovative platform technology EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced today it has reached an agreement with Embolitech to acquire an innovative...

Read More »

All Topics

COVID-19 Response Suppliers COVID-19 Response:
Can Your Company Help Provide Critical Supplies?

We are using the power of our platform to aid in the mass shortage of critical supplies. If your company can help provide supplies, capabilities, or materials for products such as N-95 Masks and Tyvek SuitsPlease let us know.

COVID-19 Response Suppliers